Brittany Lovely

Data from the phase 2 EVOKE-02 trial support further assessment of sacituzumab govitecan plus pembrolizumab as a frontline treatment for metastatic non–small cell lung cancer.

Investigators report a progression-free survival benefit with osimertinib plus chemotherapy in EGFR-mutated non–small cell lung cancer across all subgroups in the phase 3 FLAURA2 study.

Investigators report a higher recurrence-free survival rate for patients receiving a pediatric-inspired protocol regimen compared with an adult chemotherapy regimen in a retrospective review.

Better biology is needed to accurately determine risk stratification features in patients with clear cell renal cell carcinoma.

The overall survival benefit of erdafitinib supports molecular testing of FGFR in all patients with metastatic urothelial carcinoma, according to an expert from University Paris-Saclay in France.

Data from the phase 2 DESTINY-CRC02 study support the use of trastuzumab deruxtecan at a dose of 5.4 mg/kg every 3 weeks for patients with HER2-positive metastatic colorectal cancer.

Results from a phase 1/2a trial show that efficacy was maintained when BNT211 was used with or without a CLDN6-encoding mRNA vaccine for patients with relapsed/refractory advanced solid tumors.

Older patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer maintain a clinically meaningful absolute reduction in risk of distant relapse and invasive disease following treatment with abemaciclib and endocrine therapy.

In a final overall survival analysis of the phase 3 PROpel study, abiraterone actetate/olaparib demonstrates a sustained trend toward overall survival for metastatic castration-resistant prostate cancer vs standard-of-care abiraterone.

Patients with advanced biliary tract cancer experience modest clinical benefit following treatment with atezolizumab and cisplatin/gemcitabine with or without bevacizumab.

Real-world data associate axicabtagene ciloleucel with temporarily worse quality of life in patients with diffuse large B cell lymphoma, transformed follicular lymphoma, or follicular lymphoma, which improves within 1-year post-infusion.

Long-term findings from the phase 2 GeparOLA trial indicate that olaparib plus paclitaxel and carboplatin did not result in further benefit vs paclitaxel, and carboplatin for patients with HER2-negative, homologous recombination–deficient early breast cancer.

The prespecified overall survival analysis of the phase 3 monarchE trial when abemaciclib was added to endocrine therapy in patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer.

Data from the phase 2 LITESPARK-003 trial demonstrated antitumor activity and a well-tolerated safety profile with belzutifan plus cabozantinib in patients with clear cell renal cell carcinoma.

Findings from the phase 1/2 ReFocus study highlighted that RLY-4008 is a potentially transformative agent for the treatment of FGFR inhibitor–naïve, FGFR-mutant cholangiocarcinoma.

Long-term follow-up of the phase 2 DESTINY-Gastric02 study revealed fam-trastuzumab deruxtecan-nxki continues to show promise in locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

The CDK4/6 inhibitor dalpiciclib in combination with letrozole or anastrozole improved progression free survival in patients with treatment-naïve advanced breast cancer.

EGFR C797X mutations identified as leading cause of acquired resistance to osimertinib, according to real-world data from 2022 WCLC.

Findings from the phase 3 ASCEMBL trial indicated that asciminib as a treatment for chronic myelogenous leukemia in chronic phase could represent a new standard of care.

A 100% clinical complete response rate was observed when patients with stage II/III mismatch repair-deficient locally advanced rectal cancer were treated with dostarlimab.

Alpelisib combined with fulvestrant represents a viable treatment option for patients with hormone receptor–positive, HER2-negative advanced breast cancer, regardless of mutation status.

Compared with chemotherapy, sacituzumab govitecan led to better progression-free survival outcomes in patients with hormone receptor–positive, HER2-negative breast cancer.

A comparison of axicabtagene ciloleucel and tisagenlecleucel for patients with follicular lymphoma yielded comparable outcomes.

The phase 1b/2 KontRASt-01 trial demonstrated a positive safety profile of JDQ443 for patients with KRAS G12C-mutant solid tumors.

Data from a retrospective head-to-head analysis of pacritinib vs ruxolitinib showed that the former was more favorable in terms of symptom response for patients with myelofibrosis and thrombocytopenia.

In patients with bacillus Calmette-Guérun–unresponsive non-muscle invasive bladder cancer who are being treated with nadofaragene firadenovec, elevated levels of antibody titers may be able to predict efficacy.

Results from the phase 3 JUPITER06 trial demonstrated positive outcomes with toripalimab plus platinum-based chemotherapy in patients with treatment-naïve advanced or metastatic esophageal squamous cell carcinoma.

Findings from a phase 2 trial indicate that the use of neoadjuvant osimertinib may hold promise in a population of patients with EGFR-mutated non–small cell lung cancer.

Updated results confirmed the safety and efficacy of the quadruplet regimen of fixed-dose isatuximab-irfcc in combination with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with no immediate intent for transplant.

In line with responses seen at the primary analysis, final results of a phase 2 trial support activity of trastuzumab deruxtecan in HER2-positive metastatic CRC.